Vascudyne is developing, manufacturing, and commercializing regenerative acellular in-vitro grown “allograft” tissue.
Vascudyne has raised $4.0M in total funding. The most recent round was Grant. The last funding was announced in June 2025.
Vascudyne's investors include Congressionally Directed Medical Research Programs, Regenerative Medicine Minnesota.
Vascudyne is headquartered in Plano, United States.
Vascudyne is developing, manufacturing, and commercializing regenerative acellular in-vitro grown “allograft” tissue.
Vascudyne is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vascudyne — Funding & Investors." VCBacked, June 1, 2025, https://www.vcbacked.co/company/vascudyne. Accessed September 30, 2026.
VCBacked. (2025). Vascudyne — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/vascudyne
{{cite web |title=Vascudyne — Funding & Investors |url=https://www.vcbacked.co/company/vascudyne |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated